Zevra Therapeutics Selects Orsini As The Specialty Pharmacy Provider For OLPRUVA
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics (NASDAQ:ZVRA) has selected Orsini Specialty Pharmacy as the pharmacy partner for OLPRUVA, a medication for managing urea cycle disorders. This partnership aims to enhance the distribution and accessibility of OLPRUVA for patients.
June 18, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zevra Therapeutics has partnered with Orsini Specialty Pharmacy to distribute OLPRUVA, a treatment for urea cycle disorders. This partnership could improve the accessibility and distribution of OLPRUVA, potentially boosting Zevra's revenue and market presence.
The partnership with Orsini Specialty Pharmacy is likely to improve the distribution and accessibility of OLPRUVA, which could lead to increased sales and revenue for Zevra Therapeutics. This positive development is expected to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100